GlassScriptPhysician profile
Jairo B Cruz
NPI 1609163153
$21,239.95
in general payments reported to CMS, 2019-2025
34 companies · $401 in 2025
The $401 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,930 · 2020: $317 · 2021: $490 · 2022: $1,207 · 2023: $630 · 2024: $16K · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $16K · Food and Beverage: $1,114 · Long Term Medical Supply Or Device Loan: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $16,000.00 |
| Food and Beverage | $1,114.29 |
| Long Term Medical Supply Or Device Loan | $181.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $16,017.00 | 2023-2024 | |
| Stryker Corporation | $1,366.05 | 2019-2024 | Citrefix, Allograft Bio-Implants, Graftjacket |
| Smith+Nephew, INC. | $1,161.36 | 2019-2024 | Grafix Pl, Collagenase Santyl, Regranex |
| Organogenesis INC. | $514.18 | 2019-2023 | Puraply |
| Crossroads Extremity Systems, LLC | $423.79 | 2019 | |
| Integra Lifesciences Corporation | $303.72 | 2019-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Paratek Pharmaceuticals, INC. | $227.18 | 2020-2025 | Nuzyra |
| Horizon Therapeutics Plc | $199.23 | 2020-2023 | Krystexxa |
| Zyla Life Sciences, INC. | $175.57 | 2019-2020 | |
| Nevro Corp. | $135.21 | 2022-2024 | Senza |
| Kerecis Limited | $109.18 | 2019-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Kci USA, INC. | $57.90 | 2021-2022 | |
| Next Science LLC | $47.95 | 2021-2023 | Surgx, Xperience, Blastx |
| Bioventus LLC | $43.02 | 2019-2021 | |
| Sanara Medtech INC. | $35.01 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medela LLC | $34.85 | 2020 | |
| Zimmer Biomet Holdings, INC. | $34.56 | 2020 | |
| Averitas Pharma INC. | $34.28 | 2024-2025 | Qutenza |
| Orthofix Medical, INC. | $31.76 | 2019-2021 | |
| Triad Life Sciences INC. | $28.90 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $28.80 | 2023 | Seglentis |
| Mvp Orthopedics INC | $25.46 | 2021 | |
| Sandoz INC. | $24.69 | 2019 | |
| Treace Medical Concepts, INC. | $22.37 | 2022 | |
| Hartmann USA, INC. | $22.21 | 2025 | Zetuvit Plus 10x10 P10 |
| Orpyx Medical Technologies US INC. | $21.31 | 2023 | Orpyx Si |
| Allergan, INC. | $17.66 | 2020 | |
| Ets Wound Care LLC | $15.88 | 2023 | |
| Wright Medical Technology, INC. | $15.03 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $14.48 | 2019 | |
| Medtronic, INC. | $14.23 | 2022 | |
| Mimedx Group, INC. | $13.49 | 2025 | |
| Grt US Holding, INC. | $12.74 | 2020 | |
| Depuy Synthes Sales INC. | $10.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jairo Cruz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.